United States Tardive Dyskinesia Therapeutics Market Insights Forecasts to 2033

• The United States Tardive Dyskinesia Therapeutics Market Size was valued at USD 2.41 Billion in 2023.
• The Market Size is Growing at a CAGR of 7.61% from 2023 to 2033.
• The United States Tardive Dyskinesia Therapeutics Market Size is Expected to Reach USD 5.02 Billion by 2033.

The United States Tardive Dyskinesia Therapeutics Market Size is expected to reach USD 5.02 billion by 2033, at a CAGR of 7.61% during the forecast period 2023 to 2033.

Market Overview

Tardive dyskinesias (TDs) are involuntary movements of the tongue, lips, face, trunk, and extremities that develop in individuals taking long-term dopaminergic antagonist medicines. TDs appear to have existed before to the advent of neuroleptics, despite the fact that they are linked to their usage. Individuals who suffer from schizophrenia and other neuropsychiatric conditions are particularly susceptible to developing TDs following exposure to anticholinergics, poisons, drugs of abuse, and conventional neuroleptics. The patient population in the United States has experienced a significant rise in knowledge of Tardive Dyskinesia (TD). This illness is a kind of movement disorder that develops when antipsychotics are used for an extended period of time. The workshop on tardive dyskinesia treatments awareness was arranged by the Gerontological Advanced Practice Nurses Association (GAPNA) and ran from May 1st to May 7th, 2022. Since 2018, the program has been carried out annually in each of the 50 states of the United States in cooperation with Neurocrine Biosciences. Antipsychotic medications are being used more often to treat bipolar disorder, schizophrenia, and schizoaffective disorder, which is increasing the prevalence of this illness. This is increasing the need for tardive dyskinesia treatment strategies that are successful for this condition.

Report Coverage

This research report categorizes the market for United States tardive dyskinesia therapeutics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States tardive dyskinesia therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the United States tardive dyskinesia therapeutics market.

Driving Factors

Persistent and permanent tardive dyskinesia is most common in patients receiving treatment for neurological illnesses such as bipolar disorder, schizoaffective disorder, and schizophrenia. Furthermore, it is not uncommon, and one of the main reasons for the rising incidence of this illness is that anyone receiving antipsychotic medication treatment runs the risk of developing it. During the projection period, there will be a rise in demand for tardive dyskinesia therapies due to an increase in antipsychotic drug consumption.

Restraining Factors

The high costs and unclear returns on investment associated with research may make pharmaceutical corporations reluctant to fund it. The process of creating novel medicines for this illness is expensive and time-consuming. Pharmaceutical companies may find it less appealing to invest in this disease because to the significant expenses associated with research & development and regulatory approval.

Market Segment

• In 2023, the valbenazine segment accounted for the largest revenue share over the forecast period.

Based on the drug, the United States tardive dyskinesia therapeutics market is segmented into deutetrabenazine, valbenazine, and others. Among these, the valbenazine segment has the largest revenue share over the forecast period. Treating tardive dyskinesia (uncontrollably moving the tongue, face, or other body parts) involves the use of valbenazine. Furthermore, Huntington's disease-related chorea (uncontrollably abrupt movements) is treated with valbenazine (an inherited condition that causes the progressive disintegration of nerve cells in the brain).

• In 2023, the hospital pharmacies segment accounted for the largest revenue share over the forecast period.

On the basis of distribution channel, the United States tardive dyskinesia therapeutics market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment has the largest revenue share over the forecast period. The reason for this segment's domination is that most treatment drugs can only be prescribed by qualified medical professionals at hospitals following a comprehensive evaluation. The need for early diagnosis and efficient treatment options in hospital settings will expand as more patients seek treatment for this ailment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United States tardive dyskinesia therapeutics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Mitsubishi Tanabe Pharma Corporation
• Teva Pharmaceutical Industries Ltd.
• Neurocrine Biosciences, Inc.
• SOM BIOTECH
• Luye Pharma Group
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In May 2022, At the American Psychiatric Association (APA), Neurocrine Biosciences presented research results on the use of INGREZZA capsules as tardive dyskinesia treatments. The results shown that administering the drug (40 mg or 80 mg) once daily for 48 weeks resulted in notable reductions in TD symptoms as assessed by doctors and patients, while keeping psychiatric symptom stability.

Market Segment

This study forecasts revenue at regional, and country levels from 2022 to 2033. Spherical Insights has segmented the United States tardive dyskinesia therapeutics market based on the below-mentioned segments:

United States Tardive Dyskinesia Therapeutics Market, By Drug

• Deutetrabenazine
• Valbenazine
• Others

United States Tardive Dyskinesia Therapeutics Market, By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies